Details for New Drug Application (NDA): 204417
✉ Email this page to a colleague
The generic ingredient in ELEPSIA XR is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 204417
Tradename: | ELEPSIA XR |
Applicant: | Tripoint |
Ingredient: | levetiracetam |
Patents: | 5 |
Pharmacology for NDA: 204417
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 204417
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417 | NDA | Sun Pharma Advanced Research Company Limited | 47133-574 | 47133-574-13 | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (47133-574-13) |
ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417 | NDA | Sun Pharma Advanced Research Company Limited | 47133-574 | 47133-574-83 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47133-574-83) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
Approval Date: | Dec 20, 2018 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 3, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 22, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 31, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription